Introduction
============

Acute myeloid leukemia (AML) is a heterogeneous disorder of hemopoietic stem cells.[@b1-cmr-3-157] Despite improved treatment of AML in recent years, the outcome remains dismal, with only approximately 30% of patients showing long-term survival.[@b2-cmr-3-157] Factors determining survival include age, cytogenetic aberrations, number of previous antileukemia treatments, and molecular defects in leukemic cells.[@b1-cmr-3-157]--[@b3-cmr-3-157] In patients with a normal karyotype, mutations in certain oncogenic kinases, such as FLT3 or KIT,[@b4-cmr-3-157] determine the prognosis in AML.[@b3-cmr-3-157],[@b5-cmr-3-157]--[@b15-cmr-3-157] Blast cell proliferation and dissemination may be triggered by additional factors, including expression of certain homing receptors and the bone marrow microenvironment.[@b16-cmr-3-157]--[@b23-cmr-3-157]

A number of pharmacologic approaches have been proposed to counteract leukemic cell growth in AML. A straightforward approach is to develop multikinase inhibitors acting on one or more critical signaling pathways associated with leukemic cell growth, proliferation, and/or differentiation.[@b24-cmr-3-157] In fact, various multikinase inhibitors can simultaneously inhibit multiple signaling pathways involved in AML cell growth and survival.[@b25-cmr-3-157]--[@b34-cmr-3-157]

LY2457546 is a novel multikinase inhibitor with properties similar to LY2401402, which was previously shown to have an antileukemic effect in MV4-11 cells containing an FLT3-ITD mutation.[@b35-cmr-3-157],[@b36-cmr-3-157] LY2457546 has a spectrum of kinase inhibition that is distinct from that of other multikinase inhibitors, including sunitinib. For example, LY2457546 inhibits several of the ephrins and Tie-2[@b37-cmr-3-157] ([Table 1](#t1-cmr-3-157){ref-type="table"}). Based on this information, a pharmacokinetic/pharmacodynamic model was developed using in vitro and in vivo animal data to estimate the biologically effective dose range for LY2457546 in humans,[@b38-cmr-3-157] and to identify a safe starting dose for a first-in-human dose-escalation study in patients with AML. Using this predictive model, the primary objective of this study was to confirm the safety and the biologically effective dose range of LY2457546 in patients with AML. As secondary objectives, we evaluated the pharmacokinetic profile of LY2457546 and changes in pharmacodynamic markers (such as changes in phosphoprotein expression in circulating AML blasts) after LY2457546 administration. Moreover, the potential risk of drug--drug interactions by combining LY2457546 with drugs known to be metabolized by cytochrome P450 (CYP) 3A4, CYPP2D6, and CYP2C9 were assessed.

Materials and methods
=====================

Study design
------------

This first-in-human monotherapy safety study was divided into three parts to evaluate a possible drug--drug interaction risk of LY2457546, and to confirm the predicted pharmacokinetic/pharmacodynamic relationship of LY2457546 in humans ([Figure 1](#f1-cmr-3-157){ref-type="fig"}). The first part (visit 0) consisted of a single-dose, 48-hour pharmacokinetic profile evaluation of LY2457546 (from day day −2 to day 1) and a baseline assessment of a drug--drug interaction cocktail. The second part (visit 1) was a multidose assessment for four weeks (for two weeks after an amendment) of daily oral administration of LY2457546. During visit 1, a 12-hour pharmacokinetic profile of LY2457546 was obtained. The third part (visit 2) evaluated the 48-hour pharmacokinetic profile of LY2457546 in the presence of the drug--drug interaction cocktail after LY2457546 was stopped. Treatment was resumed as daily dosing for the remainder of the study, provided the patient showed clinical benefit.

The study was approved by the ethics committee of the Medical University of Vienna and the Austrian Federal Ministry of Health according to the International Conference on Harmonization guidelines, the Declaration of Helsinki on clinical trials involving human subjects, the recommendation for conducting clinical first-in-human dose studies by the Committee For Medicinal Products For Human Use ([www.emea.europa.eu/pdfs/human/swp/2836707enfin.pdf](www.emea.europa.eu/pdfs/human/swp/2836707enfin.pdf) from August 20, 2007, and the Austrian Medicinal Products Act (AMG).

Enrolment criteria
------------------

The inclusion criteria were: age at least 18 years; diagnosis of relapsed or refractory AML; ineligibility for bone marrow transplantation or induction/consolidation chemotherapy;[@b39-cmr-3-157] ≥10% of blasts in peripheral blood at baseline; willingness to undergo two bone marrow aspirates during visits 0 and 2 to evaluate changes in phosphoprotein expression in AML blasts; recovery from the acute toxic effects of previous treatment; performance status 0 to 2 on the Eastern Cooperative Oncology Group scale; discontinuation of all previous therapies for cancer for at least 14 days (hydroxyurea used to control the peripheral blast cell count was permitted until 72 hours before study drug administration at visit 1); bilirubin ≤2 × below the upper limit of normal, alanine aminotransferase and aspartate aminotransferase ≤5 × upper limit of normal; serum creatinine ≤1.5 × upper limit of normal; no known active renal disease; activated prothrombin time and prothrombin time at or below upper limit of normal. Male and female patients agreed to use a reliable method of birth control during dosing and for six months following the last dose of study drug. Females of childbearing potential had to have had a negative serum pregnancy test at least seven days prior to the first dose of study drug. Monthly pregnancy tests were conducted in accordance with Article 30 of the AMG. Finally, patients had to be compliant with all protocol-defined procedures and be able to swallow capsules.

Patients were excluded if they had acute promyelocytic leukemia as defined by World Health Organization criteria,[@b39-cmr-3-157] chronic myeloid leukemia in blast crisis, leukemic involvement of the central nervous system (eg, signs, symptoms or a history of leukemic meningitis, must have had a negative lumbar puncture within two weeks of study enrolment), serious concomitant disorders (eg, active bacterial, fungal, or viral infection), active second primary malignancy that could affect study conduct or interpretation of study results, serious pre-existing medical conditions (eg, persistent history of occlusive coronary artery disease, uncontrolled hypertension with systolic \> 140 mmHg and diastolic \>90 mmHg, risk of bleeding due to active gastrointestinal bleeding or anticoagulant therapy, except for low-dose therapy to maintain patency of central venous access devices), major surgery within four weeks of study enrolment, positive test results for human immunodeficiency virus antibodies, hepatitis B surface antigen, or hepatitis C antibodies, and women who were pregnant or lactating.

Drug formulation and schedule of administration
-----------------------------------------------

LY2457546 was taken as a once-daily oral capsule in the morning before breakfast. All patients had been fasting for approximately eight hours prior to the LY2457546 dose and for two hours prior to dosing of the drug cocktail. After oral administration, patients were asked to wait for at least 60 minutes prior to having breakfast. For at least two weeks prior to the start of the study and until the final pharmacokinetic sample was collected, patients were requested to abstain from beverages containing grapefruit or pomelo fruit, and food containing broccoli, cabbage, cauliflower, turnips, collard, mustard, or charbroiled meats. If a patient continued taking dietary supplements, such as vitamins or St John's wort, these were recorded as comedication and considered in the interpretation of the pharmacokinetic data.

Drug--drug interaction cocktail
-------------------------------

The drug--drug interaction cocktail consisted of midazolam 0.2 mg, dextromethorphan 30 mg, and tolbutamide 500 mg as specific probes to assess the CYP3A4, CYP2D6, and CYP2C9 metabolic pathways, respectively.[@b40-cmr-3-157]--[@b43-cmr-3-157]

Treatment assessment
--------------------

Investigators assessed baseline "toxicity" according to institutional and previously published guidelines,[@b44-cmr-3-157] which included establishing baseline neutropenia and other bone marrow deficiencies as a result of AML. Assessment of dose-limiting toxicity was graded following the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The following adverse events were deemed to be dose-limiting toxicities if they were likely to be drug-related: ≥Grade 3 nonhematological toxicity (except for nausea/vomiting without maximal symptomatic/prophylactic treatment), CTCAE Grade 3 or 4 febrile neutropenia, CTCAE Grade 3 infection with Grade 3 or 4 neutropenia, untreated diarrhea Grade ≥3, CTCAE Grade 4 neutropenia or thrombocytopenia until four weeks after the end of the treatment course, unless the respective Grade 4 cytopenia was pre-existing. In patients who required platelet substitution to maintain a CTCAE Grade \<4 before treatment, a CTCAE Grade 4 thrombocytopenia after treatment did not constitute a dose-limiting toxicity.

Due to the cardiac toxicities observed with other multikinase inhibitors, the risks of developing Grade 3/4 QTc prolongation or increased blood pressure were evaluated. For QTc prolongation, the following dose-limiting toxicity definitions were used: any CTCAE Grade 4 QTc prolongation or three of six patients with CTCAE Grade 3 and a definitive association between QTc prolongation and LY2457546 exposure. Provided that other factors known to prolong QTc intervals had been minimized or excluded, assessment of QTc prolongation was based on Fridericia's corrected QTc evaluation (QTcF) at the end of each cohort. In the event that CTCAE Grade 3 QTc prolongation was observed (defined as an interval \>500 msec or an increase of QTc of \>60 msec from baseline with no medically significant symptoms), a confirmatory 12-lead electrocardiogram was required before LY2457546 doses were omitted until the QTc interval returned to \<500 msec or below the 60 msec upper boundary. In the event that CTCAE Grade 4 QTc prolongation was observed (defined as an interval \>500 msec or an increase of QTc of \>60 msec from baseline with life-threatening signs or symptoms), patients would be considered for withdrawal from the study on the basis of dose-limiting toxicity.

Dose escalation
---------------

Dose escalation was planned up to the maximum tolerated dose. The decision to dose-escalate to the next cohort and dose level was planned on the basis of safety and available pharmacokinetic and pharmacodynamic data from the previous dose cohort. This decision was planned to occur in agreement with the investigators and sponsor. Written notification of this decision was to be sent to the site and appropriate institutional ethics committee. No intrapatient dose escalation beyond the original assigned cohort was permitted.

At the end of the first cohort, the pharmacokinetic profiles for the LY2457546 and drug cocktail were reviewed to confirm the predicted exposures for the following doses. The starting dose was 50 mg/day, and the maximum planned dose was 500 mg/day. The first cohort included three patients. For all subsequent doses where a pharmacological effect was expected, the cohort size was increased to six patients. All patients in a given cohort had to complete the first multidose cycle prior to enrolling patients at the next dose level. If two or more of six patients experienced a dose-limiting toxicity at any dose level, the maximum tolerated dose was exceeded and dose escalation ceased. For QTc prolongation, Grade 3 QTc prolongation was required in three of six pts to declare a dose-limiting toxicity, while all Grade 4 QTc prolongations were declared as dose-limiting toxicity.

Pharmacokinetic assessment
--------------------------

Pharmacokinetic parameters were analyzed using standard, noncompartmental methods of analysis (WinNonlin Enterprise, version 5.2). It was planned to calculate the following: time to maximum concentration (T~max~), maximum plasma concentration (C~max~), area under the plasma concentration versus time curve (AUC), and oral clearance following LY2457546 administration.

Pharmacodynamic assessment
--------------------------

Based on the predictive pharmacokinetic/pharmacodynamic model, the biologically effective dose range was anticipated to be between 100 mg and 400 mg. The recommended biologically effective dose should provide a minimum of 50% median inhibition of one or all phosphoproteins for 24 hours (the minimum requirement to declare a biologically effective dose would be based on pFLT3 inhibition), should provide durable AML blast reduction compared with baseline in at least half of the patients (for at least one month), and be lower than the maximum tolerated dose.

Flow cytometry
--------------

As previously described, blood samples were collected to evaluate phosphoprotein levels using flow cytometry.[@b45-cmr-3-157] In order to ensure appropriate assessment of changes in phosphoprotein expression, samples had to be shipped within 48 hours to a central laboratory (Esoterix, Mechelen, Belgium) after blood or bone marrow aspirates were obtained. Upon arrival, cells were prepared for cytometric assessment, gated based on side versus forward scatter, and subsequently for CD45, CD34 (CD45-PerCP and CD34-PE, Becton Dickinson, San Jose, CA) and CD11b (CD11b-Pacific Blue, Beckman Coulter, Miami, FL, Esoterix custom conjugate) expression. This gating approach allowed the separation of four distinct subgroups, ie, CD34^+^CD11b^−^, CD34^+^CD11b^+^, CD34^−^CD11b^−^, and CD34^−^CD11b^+^. For each of these subgroups, the following phosphoproteins were determined with their respective isotype control (all antibodies were obtained from Cell Signaling Technology \[CST\], Danvers, MA): phospho-FLT3/CD135 (Y591-Alexa Fluor 647, CST, Esoterix custom conjugate); phospho-c-KIT/CD117 (Y719, No ST\#3391L, CST); phospho-p44/42 extracellular signaling-regulated kinase 1/2 (pERK1/2, T202/Y204, Alexa Fluor 647, No 4375, CST); phospho-AKT (S473-Alexa Fluor 647, No 4075, CST); phospho-phospho-tyrosine-Y100 (pY100) (Alexa Fluor 488, No 9415, CST); phospho-S6 ribosomal protein (pS6) (S235/236-Alexa Fluor 647, CST, Esoterix custom conjugate). Phospho-STAT5 was determined along with isotype control using anti-phospho-STAT5 (Y694, No 612599, Becton Dickinson). The isotype controls used for the phosphoproteins were matched with the primary antibodies at the identical concentrations used in the assay. The phospho c-KIT (pcKIT) was developed using a goatantirabbit Alexa Fluor 647 (both used at 1 μg per staining reaction). In all cases, the staining reactions were carried out in 50 μL total volumes in phosphate-buffered saline with 3.4% bovine serum albumin.

Flow cytometry was performed on a 3-laser Becton Dickinson FACS-Canto-II cytometer with custom filter sets designed to optimize the collection of Alexa 647 and Alexa 700 signals, in lieu of tandem dyes. The instrument was set up using QC3 beads (Bangs Laboratories, Fishers, IN), Spherotech 1 peak Rainbow Mid-Range beads (Spherotech, Lake Forest, IL), and CaliBrite APC beads (Beckton Dickinson) for the daily monitoring of instrument performance within an accepted "window of analysis". Full spectrum fluorescent calibration particles (Spherotech) were also run with each assay to determine the molecules of equivalent fluorescence of the phosphoproteins. Each sample was analyzed using a direct data exchange link between WinList 6.0 (Verity Software House, Topsham, MA) and Microsoft Excel (Microsoft, Redmond, WA). All data gating, displaying, and processing were conducted in WinList.

Antileukemia response assessment
--------------------------------

Based on the recent World Health Organization criteria,[@b46-cmr-3-157] responses were determined by assessing bone marrow aspirates. In this study, we also considered a pharmacodynamic response if a sustained reduction in peripheral blast cell counts was observed (longer than four weeks).

Results
=======

Five patients (A--E) were enrolled from February to August 2009 and received 50 mg LY2457546 once daily. Except for one patient, all had an original diagnosis of primary AML. The median age of the patients was 68 years, with only one patient younger than 60 years ([Table 2](#t2-cmr-3-157){ref-type="table"}). The majority had been diagnosed with leukemia for at least 18 months. All patients had undergone at least a full regimen of induction chemotherapy. Prior to entering the trial, all patients had received hydroxyurea to control blast cell counts. Two patients had medically treated hypertension at study entry, which did not deteriorate as a result of LY2457546 administration.

During visit 1, the first three patients were discontinued from treatment on days 17, 20, and 30. The first two patients were discontinued due to disease progression. The third patient (C) showed Grade 3 muscle weakness on day 10 which was considered to be drug-related and deemed a dose-limiting toxicity. Given the early discontinuation of the first three patients, the protocol was amended to shorten the first cycle to a 14-day cycle to obtain a pharmacokinetic profile after 14 days of multiple dosing of LY2457546. Two more patients (D, E) were treated after this amendment and were discontinued on days 7 and 17. The reason for discontinuation in these two patients was disease progression based on clinical symptoms. Three patients died a few days after discontinuation of LY2457546, primarily due to sepsis and progressive leukemia which was no longer controlled by post-study administration of hydroxyurea. In one of the five patients (B) we observed a significant but transient decrease in leukocyte and blast cell counts through day 10 ([Figures 2A and 2B](#f2-cmr-3-157){ref-type="fig"}).

The most frequently observed adverse events in this study were headache, epistaxis, petechiae, and hypokalemia (n = 3 each, see [Table 3](#t3-cmr-3-157){ref-type="table"}). All these adverse events were graded as CTCAE 1 or 2, and were considered to be related to the disease rather than the study drug. Grade 3 adverse events included two cases of febrile neutropenia, hypotension, and infection-related adverse events, including anal abscess, pneumonia, catheter-related infection, fungal sepsis, neutropenic sepsis, and breast cellulitis ([Table 3](#t3-cmr-3-157){ref-type="table"}). As expected for this patient population, bone marrow was already depressed at study entry. A transient Grade 4 hypophosphatemia was observed and corrected with calcium phosphate infusions. A Grade 4 hemorrhage was considered to be related to disease progression. All recorded Grade 3 and 4 adverse events were not considered to be related to the study drug, with the exception of a Grade 3 generalized muscle weakness in patient C, who developed this adverse event 14 days after starting LY2457546 administration, and the adverse event resolved within seven days of stopping LY2457546. Because of its likely association with LY2457546, and after excluding other potential medical or drug-related causes, this toxicity was deemed to be a dose-limiting toxicity for this cohort.

Because other multikinase inhibitors have dose-dependent adverse effects on cardiac conductivity,[@b47-cmr-3-157] cardiac monitoring with a detailed QTc risk assessment was implemented in this study.[@b48-cmr-3-157] In three patients abnormal electrocardiograms were present at study entry, which were not deemed medically significant. QTc prolongation after Bazet and Fridericia corrections were not present after the single-dose administration ([Figure 3](#f3-cmr-3-157){ref-type="fig"}). Compared with baseline, the QTc prolongation remained unchanged over the 48-hour follow-up period following single-dose administration. For the multipledose treatment, increased QTc prolongation was observed only for patient D after eight days of treatment. A relationship with the study drug appears unlikely, because the exposure of patient D to LY2457546 was lower than in other patients during the multiple-dose study period ([Figure 3](#f3-cmr-3-157){ref-type="fig"}). In addition, patient D also suffered from goiter and showed a steep decline in T3, T4, and TSH in parallel with QTc prolongation, strongly suggesting that thyroid function influenced the QTc interval (data not shown).

An unexpected pharmacokinetic profile was observed in all five patients, which was substantially different from the animal pharmacokinetic studies (data on file, Eli Lilly and Company, [Figures 3](#f3-cmr-3-157){ref-type="fig"} and [4](#f4-cmr-3-157){ref-type="fig"}). Extensive accumulation of plasma LY2457546 was observed, and the compound did not appear to enter an elimination phase, as assessed by pharmacokinetic day profiles following single (visit 0) and multiple oral doses (visits 1 and 2, [Figures 4A, 4B, and 4C](#f4-cmr-3-157){ref-type="fig"}). As a result of this observation and the intraindividual variability of LY2457546, no terminal elimination half-life could be defined for any of the patients. Hence, the only reported parameters are C~max~, T~max~, C~last~, and t~last~, and the only calculated parameter was AUC~0--24~ ([Table 4](#t4-cmr-3-157){ref-type="table"}). Furthermore, plasma LY2457546 exposures were much higher than expected.

No consistent drug--drug interactions with midazolam, tolbutamide, and dextromethorphan were observed ([Figures 4D, 4E and 4F](#f4-cmr-3-157){ref-type="fig"}), suggesting that any interference with CYP3A4, CYPP2D6, or CYP2C9 was minimal or not present. This was consistent with the previous in vitro drug--drug interaction studies (data on file, Eli Lilly and Company).

In previous studies of multikinase inhibitors in AML, Western blotting was used to determine the pharmacodynamic effects of sunitinib.[@b32-cmr-3-157] Here, we used a novel and validated quantitative flow cytometry-based assay to evaluate changes in phosphoprotein expression in AML blasts. Although we observed some variability in the makeup of the leukemia cell population, all five patients had CD34^+^blasts, and three of the five patients had the CD34^+^CD11b^−^ expression phenotype ([Figure 5](#f5-cmr-3-157){ref-type="fig"}). Based on this expression of CD34 and CD11b, we defined four subgroups, which were evaluated for phosphoprotein expression. In all five patients, baseline expression of pFLT3, pcKIT, pS6, and pY100 was observed, especially in the CD34^+^CD11b^−^ cells. However, pAKT, pERK, and pSTAT were not expressed ([Supplemental Figure S1](#s1-cmr-3-157){ref-type="supplementary-material"}). Clear separation from the isotype controls was found for pFLT3, pcKIT, pS6, and pY100. As exemplified by the pFLT3 expression, all patients (except patient E) had a similar range of pFLT3 expression ([Supplemental Figure S2](#s2-cmr-3-157){ref-type="supplementary-material"}). Compared with pretreatment phosphoprotein expression, we detected a downregulation of median phosphoprotein expression for pFLT3, pcKIT, and pS6 in most of the patients ([Figure 6](#f6-cmr-3-157){ref-type="fig"} and [Supplemental Figure S3](#s3-cmr-3-157){ref-type="supplementary-material"}). Following single-dose administration, pFLT3, pcKIT, and pS6 expression was reduced at four hours after administration of LY2457546 in three of the five patients (patients A, C, and E, [Supplemental Figure S3](#s3-cmr-3-157){ref-type="supplementary-material"}). After multiple dosing of LY2457546, we observed reduced expression of pFLT3 and pcKIT in at least three patients (B, C, and E), and a similar trend was observed for pS6 in another three patients (patients A, B, and E, [Figure 6](#f6-cmr-3-157){ref-type="fig"} and [Supplemental Figure S4](#s4-cmr-3-157){ref-type="supplementary-material"}). Interestingly, phosphoprotein expression increased in all patients at the time of progression or after treatment with LY2457546 had ended, and responded briefly to retreatment with hydroxyurea (patients B, C, and E, [Figure 6](#f6-cmr-3-157){ref-type="fig"}, [Supplemental Figure S4](#s4-cmr-3-157){ref-type="supplementary-material"}).

Discussion
==========

In the present study, we evaluated the safety and biological activity of LY2457546 in patients with relapsed AML. Due to an unfavorable pharmacokinetic profile for LY2457546, the study was terminated early without establishing a biologically effective dose range. When considering the conduct of a first-in-human dose study in patients with relapsed AML, it is necessary to balance the need to evaluate safety with the need to treat a rapidly progressing malignancy. Therefore, new molecular entities with an acceptable preclinical safety profile and antileukemic activity in animal models are considered acceptable candidates for first-in-human dose trials in relapsed AML patients.

In preclinical toxicology studies, LY2457546 had toxicities similar to those reported in nonclinical studies of other multikinase inhibitors, including reversible bone marrow toxicity, minimal liver inflammation, reversible physeal dysplasia (a common finding for antiangiogenic agents in rats and dogs),[@b49-cmr-3-157] reversible lymphoid necrosis of Peyer's patches, and skin depigmentation or whitening of the hair consistent with the previously described effects of c-KIT inhibitors.[@b50-cmr-3-157] Overall, the preclinical safety profile indicated that LY2457546 had a favorable toxicity profile compared with other multikinase inhibitors.[@b51-cmr-3-157]

In addition to this favorable preclinical toxicity profile, the preclinical efficacy models with MV4-11 cells containing the FLT3-ITD mutation suggested that LY2457546 was 10-fold more potent than sunitinib in controlling leukemia growth in animals.[@b52-cmr-3-157] Based on these combined preclinical safety, efficacy, and other published inhibition profiles of similar multikinase inhibitors, a predictive pharmacokinetic/pharmacodynamic model defined 50 mg per day as a starting dose which had the potential to provide an antileukemia effect in patients.[@b38-cmr-3-157],[@b53-cmr-3-157],[@b54-cmr-3-157]

Unfortunately, the pharmacokinetic profile of LY2457546 in AML patients showed unexpected variability, and differed substantially from the preclinical pharmacokinetic data. Hence, the pharmacokinetic/pharmacodynamic model could not be leveraged for the first-in-human dose study. Variable pharmacokinetic profiles have also been reported for other multikinase inhibitors, such as sorafenib and sunitinib.[@b55-cmr-3-157],[@b56-cmr-3-157] In the case of LY2457546, the plasma pharmacokinetics suggest an accumulation likely due to a lack of elimination or to absorption issues. Such a pharmacokinetic profile is not observed for sorafenib and sunitinib. The cause for the unexpected pharmacokinetic profile of LY2457546 was not identified in this study. Protein binding may have influenced the pharmacokinetic profile of LY2457546. All AML patients in this study had a low total albumin, which raises the possibility that the unbound fraction of LY2457546 was larger than expected. However, no formal protein-binding study was conducted, and thus it was not possible to determine the influence of protein-binding on the pharmacokinetic profile of LY2457546. Like other multikinase inhibitors, such as imatinib and sunitinib, drugs altering the P450 pathway could have affected the pharmacokinetic profile of LY2457546.[@b57-cmr-3-157],[@b58-cmr-3-157] While in vitro or in vivo experiments with LY2457546 suggested the lack of such an interference (data on file, Eli Lilly and Company), animal models cannot definitively exclude such a risk in patients.[@b59-cmr-3-157]--[@b63-cmr-3-157] Hence, a drug--drug interaction assessment was conducted starting with the first cohort. A drug--drug interaction risk was not observed, as demonstrated by the unchanged plasma pharmacokinetics of P450 pathway enzyme substrates, ie, midazolam, tolbutamide, and dextromethorphan ([Figure 4](#f4-cmr-3-157){ref-type="fig"}). In the future, five-drug cocktail studies may provide a more comprehensive assessment of how hepatic metabolism may affect the pharmacokinetics of multikinase inhibitors.[@b43-cmr-3-157] Also, tolbutamide and midazolam are increasingly difficult to obtain for drug--drug interaction studies, because their pharmaceutical use is in decline or restricted in most European Union countries. Another factor influencing the pharmacokinetic profile of LY2457546 is stomach acidity, which may have affected the absorption of LY2457546.[@b64-cmr-3-157] For instance, four of our five patients were taking a proton pump inhibitor (pantoprazole), which may have altered the pharmacokinetics of LY2457546. Further, enterohepatic recycling of LY2457546 may also explain the unexpected pharmacokinetic profile. In both instances, a change in formulation of LY2457546 may help to address the observed unfavorable pharmacokinetic profile.

Despite this pharmacokinetic profile, there was little or no drug-associated QTc prolongation. Some central health authorities have expressed the concern that QTc studies are not adequately conducted in oncology trials.[@b65-cmr-3-157] However, evaluating the risk of QTc prolongation in cancer patients is not straightforward. When the pharmacokinetic profile is not known in a first-in-human dose trial, the assessment of QTc risk is further complicated by the overall condition of the study population, consisting of terminally ill patients with heavily pretreated conditions receiving several comedications and suffering from coexisting disease. Most patients in our study had previously received multiple cycles of anthracycline-based chemotherapy as part of their induction/consolidation treatment. Other potentially cardiotoxic comedications having a definite association with QTc prolongation,[@b66-cmr-3-157] such as amitriptyline, diphenhydramine, pantoprazole, fluconazole, ketoconazole, azithromycin, and ciprofloxacin, were identified in this study, but were not associated with QTc prolongation. Pre-existing medical conditions of patients in this study were more likely to interfere with electrocardiographic interpretation, ie, arterial hypertension Grade 2 (patient C), goiter (patient D), and asthma (patient E). QTc studies are generally conducted in healthy volunteers after the pharmacokinetic profile of an agent is well established.[@b47-cmr-3-157] However, recent requests from competent health authorities to investigate QTc as part of oncology first-in-human dose studies may be more motivated by concerns about the conductivity risk for specific drug classes (as in this case, where LY2457546 was classified as belonging to the multikinase inhibitor class, which also includes sunitinib and sorafenib). In contrast with other approved multikinase inhibitors, LY2457546 did not show significant electrophysiological toxicity in animals. While the potential risk of QTc prolongation was raised when LY2457546 was found to inhibit the human ether-à-go-go-related gene (hERG) at an IC~50~ of 0.2 μM, no QTc interval prolongation was observed in electrocardiograms after single or repeat doses in dogs at maximal plasma concentrations of up to 7 μg/mL (data on file, Eli Lilly and Company). Hence, it was reassuring that we only observed QTc prolongation in a patient with goiter (patient D) which was not associated with high LY2457546 concentration ([Figure 3](#f3-cmr-3-157){ref-type="fig"}).

The Grade 3 muscle weakness in one patient was reminiscent of a similar toxicity in AML patients observed with MS-275, a histone deacetylase inhibitor.[@b67-cmr-3-157] MS-275 was associated with Grade 4 neurologic toxicity, consisting of somnolence, weakness, and unsteady gait, and associated with Grade 3 laboratory abnormalities, including elevated lactate dehydrogenase, hypertriglyceridemia, and hyperglycemia.[@b67-cmr-3-157] Also, in AML studies with MLN518/tandutinib, three cases of tandutinib-related muscular weakness were reported as dose-limiting toxicities.[@b27-cmr-3-157] Based on a recent review of several FLT3 inhibitors, muscle weakness toxicity is considered an exception among other FLT3 inhibitors. The neurotoxicities observed with MS-275 and MLN518 are perhaps due to the broad inhibition profile of such type of inhibitors, which may include inhibition of the muscle-type nicotinic receptor.[@b68-cmr-3-157] For LY2457546, no such inhibition of a muscle-type nicotinic receptor has been evaluated.

Finally, we measured the pharmacodynamic effects of LY2457546 by assessing changes of phosphoproteins in blast cells using quantitative flow cytometry[@b69-cmr-3-157] and not Western blotting.[@b32-cmr-3-157] Western blotting was used in studies with sunitinib, where a reduction of pFLT3 was reported in 77% patients (10/13) at 200 mg, while lower doses showed a pFLT3 reduction in 25% of the patients (2/8). Western blotting was also used to detect a reduction in pFLT3 expression after 300 mg and 525 mg twice-daily dosing with MLN518/tandutinib.[@b27-cmr-3-157] In contrast with Western blotting, the recent progress in flow cytometry allows a quantitative assessment of basal expression of phosphoproteins[@b70-cmr-3-157] and treatmentassociated monitoring of signaling pathways.[@b45-cmr-3-157],[@b71-cmr-3-157] Based on the predictive pharmacokinetic/pharmacodynamic model, we expected an inhibition of most phosphoprotein kinases at the 50 mg/day dose. In fact, the flow cytometry studies showed an inhibition for pFLT3, pcKIT, and pS6 in three of our five patients. Surprisingly, pAKT and pERK expression was absent in all patients. This failure of detecting pAKT and pERK might be due to either a loss of expression during sample shipment or the lack of expression in patients with advanced AML. While we achieved reductions in pFLT3 levels after LY2457546 administration, the reduction was not associated with a durable reduction in blast cell counts. It is possible that flow cytometry is a more sensitive assay compared with Western blotting, and thus the 50 mg/day dose of LY2457546 was a threshold dose above which antileukemic responses may have occurred as predicted by the pharmacokinetic/pharmacodynamic model. Unfortunately, we were not able to evaluate the possibility of a dose-dependent increase in phosphoprotein inhibition and its associated antileukemic effect in this study. Nevertheless, the approach of using multiparametric flow cytometry is encouraging, and should be further evaluated in clinical trials with similar agents.

Overall, this first-in-human dose study provides a detailed approach on how to integrate the evaluation of safety (including concentration-associated QTc assessments as part of the definition of dose-limiting toxicity), pharmacokinetics and pharmacodynamics of a multikinase inhibitor in AML patients.

Supplementary figures
=====================

###### 

Flow cytometric assessment of phosphoproteins (pFLT3, pCKIT, pS6, pY100, pERK, pAkt, and pSTAT5) in peripheral CD34^+^CD11^−^ blood cells of five patients treated with a single dose and multiple doses of LY2457546. Summary representation of all five patients for pFLT3 (red), pcKIT (green), pS6 (pink), and pY100 (yellow) at predose, and after 8 and 15 days of treatment with LY2457546. Reduction of pFLT3, pcKIT and pS6 at day 8 was observed in most patients, which increased at day 15. pERK (orange), pAKT (gray), and pSTAT5 (cyan) expression was not detectable. Phosphoprotein expression is plotted as MEFL.

**Abbreviation:** MEFL, molecules of equivalent fluorescence.

###### 

Differentiation of isotype control and pFLT3 detection in five AML patients by flow cytometry. Each patient (A--E) is shown for their pFLT3 expression in peripheral blood cells after gating on CD34^+^CD11^−^ blood cells (see [Figure 4](#f4-cmr-3-157){ref-type="fig"}). Changes are shown after single dosing followed by multidosing with LY2457546. The black lines represent pFLT3 expression as detected by MEFL, while the gray lines represent the respective isotype control.

**Abbreviations:** AML, acute myeloid leukemia; MEFL, molecules of equivalent fluorescence.

###### 

Flow cytometric assessment of pFLT3, pcKIT, and pS6 in patients treated with a single dose followed by multiple doses of LY2457546 in peripheral CD34^+^CD11^−^ blood cells. Individual pharmacodynamic profiles of pFLT3 (**A**), pcKIT (**B**), and pS6 (**C**) expression following single-dose and multiple-dose LY2457546. Phosphoprotein expression is presented as MEFL. Reduction of phosphoprotein expression begins four hours after administration of LY2457546.

**Abbreviation:** MEFL, molecules of equivalent fluorescence.

###### 

Flow cytometric assessment of pFLT3, pcKIT, and pS6 in peripheral CD34^+^CD11^−^ blood cells relative to blast cell counts for patients (**A--E**) following administration of LY2457546. Expression of pFLT3, pcKIT, and pS6 at predose, day 1, day 8, day 15, and at the end of the study was measured in peripheral CD34^+^CD11^−^ blood cells by fluorescence activated cell sorting. Expression of phosphoproteins as detected by MEFL for individual patients. Patients (**A--E**) are shown in relationship to blast counts. Solid lines of blast counts indicate dosing period with LY2457546 while dotted lines of blast counts indicate time periods without LY2457546.

**Abbreviation:** MEFL, molecules of equivalent fluorescence.
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![Design of the first-in-human dose study with LY2457546. To evaluate the safety, pharmacokinetics, DDI risk, and pharmacodynamic effects of single-dose (visit 0) and multiple-dose (visit 1, visit 3n) administration of LY2457546, patients first underwent a bone marrow aspirate, which was repeated after multiple-dosing for four weeks (two weeks after amendment, visit 2). During visit 1, patients' peripheral blast cell counts and changes in phosphoprotein expression were assessed daily and weekly, respectively. The DDI cocktail was administered prior to taking a single dose (approximately seven days prior to the single dose of LY2457546) and again after two or four weeks (after amendment) of multiple doses of LY2457546 (visit 2). The pharmacokinetic profile of LY2457546 was evaluated in the absence of the DDI cocktail as a single dose (48-hour profile) and again after one week of multiple dosing (12-hour profile).\
**Abbreviations:** DDI, drug--drug interaction; AML, acute myeloid leukemia; LY, LY2457546.](cmr-3-157f1){#f1-cmr-3-157}

![Daily leukocyte and blast cell count leukocyte (upper panel) and blast cell count (lower panel) for patients A--E are displayed in relationship to the single dose and multiple doses of LY2457546. Solid lines indicate dosing period with LY2457546, while dotted lines indicate time periods without LY2457546 treatment.](cmr-3-157f2){#f2-cmr-3-157}

![QTc assessment in relationship to plasma concentration of LY2457546. Time course of LY2457546 plasma concentrations for patients A--E (panel **A**). QTcB (panel **B**) and QTcF (panel **C**) are displayed in relationship to the single dose and multiple doses of LY2457546. A summary table of changes in QTcF and QTcB shows no changes in QTc compared with plasma LY2457546 concentration.\
**Abbreviations:** QTcF, Fridericia's corrected QTc; QTcB, Bazet's corrected QTc.](cmr-3-157f3){#f3-cmr-3-157}

![Pharmacokinetic profile of LY2457546 and the drug--drug interaction cocktail compounds (midazolam/tolbutamide/dextromethorphan) with and without LY2457546. Individual LY2457546 plasma concentration versus time profiles following a single dose (visit 0, panel **A**) and multiple oral doses of 50 mg (visit 1, panel **B**; visit 2, panel **C**). Midazolam (panel **D**), tolbutamide (panel **E**), and dextromethorphan (panel **F**) plasma concentration to time profiles following cocktail of 0.2 mg midazolam, 500 mg tolbutamide, and 30 mg dextromethorphan, respectively, before and after treatment with LY2457546.\
**Abbreviation:** LY, LY2457546.](cmr-3-157f4){#f4-cmr-3-157}

![Flow cytometric assessment of blast cells. All blast cells were gated based on forward versus side scatter (left upper panel), and assessed for CD34 and CD11b expression. Individual patients (**A--E**) are shown after adjusting for appropriate gating for CD34 and CD11b expression, establishing four different expression patterns, ie, CD34^+^CD11b^−^, CD34^+^CD11b^+^, CD34^−^CD11b^−^, and CD34^−^CD11b^+^.](cmr-3-157f5){#f5-cmr-3-157}

![Flow cytometric assessment of pFLT3, pcKIT, and pS6 in peripheral CD34^+^CD11^−^ blood cells for patients (**A--E**) before and after LY2457546 administration. Expression of pFLT3, pcKIT, and pS6 at predose, day 1, day 8, day 15, and at the end of the study was measured in peripheral CD34^+^CD11^−^ blood cells by fluorescence activated cell sorting. Expression of phosphoproteins as detected by MEFL for individual patients (**A--E**) is shown in relationship to leukocyte counts. Solid lines of leukocyte counts indicate dosing period with LY2457546, and dotted lines of leukocyte counts indicate time periods without LY2457546 treatment.\
**Abbreviation:** MEFL, molecules of equivalent fluorescence.](cmr-3-157f6){#f6-cmr-3-157}

###### 

In vitro Inhibition Profile of LY21457546

                                                                                                       **Human Kinases**                              **LY2457546**   **Sunitinib**   **Sorafenib**
  --------------------------------------------------- ------------------------------------------------ ---------------------------------------------- --------------- --------------- ---------------
                                                                                                       **Biochemical Inhibition Profile IC50 (μM)**                                   
                                                                                                       **FLT4**                                       0.00156         0.00566         0.0261
                                                                                                       **RET**                                        0.00419         0.0485          0.0033
                                                                                                       **FLT3**                                       0.0051          0.00659         0.105
                                                                                                       **EPHA5**                                      0.0107          8.05            0.531
                                                                                                       **EPHB1**                                      0.0214          1.15            0.474
                                                                                                       **PDGF-Rb**                                    0.0257          0.0352          0.312
                                                                                                       **KDR**                                        0.028           0.0611          0.013
                                                                                                       **VEGF-R1**                                    0.0306          0.269           0.241
                                                                                                       **EPHA8**                                      0.0335          \>20            0.214
                                                                                                       **VEGF-R3**                                    0.0341          0.0323          0.0925
                                                                                                       **EPHA2**                                      0.0374          9.38            0.276
                                                                                                       **EPHB4**                                      0.0398          1.59            0.727
                                                                                                       **EPHB2**                                      0.0457          3.13            0.854
                                                                                                       **cKIT**                                       0.0738          0.0756          0.966
                                                                                                       **EPHA3**                                      0.0998          10.5            1.42
                                                                                                       **EPHA4**                                      0.157           11.7            3.26
                                                                                                       **EPHA7**                                      0.221           5.38            0.709
                                                                                                       **RAF**                                        0.264           \>20            0.0195
                                                                                                       **EPHA1**                                      0.616           7.08            ND
                                                                                                       **p70S6K** (percent inhibition at 20 μM)       75.9            92.3            75.6
  **Cell-Based Target Inhibition Assays IC50 (mM)**                                                                                                                                   
  **Cell line**                                       **Activator**                                    **Phospho end point**                          **LY2457546**   **Sunitinib**   **Sorafenib**
  HUVEC                                               VEGF                                             **pERK^T202Y204^**                             0.00205         0.0287          ND
  MV4-11                                              constitutively active                            **pSTA^T5Y694^**                               0.00039         0.00426         ND
  HUVEC                                               VEGF                                             **pERKp^T202Y204^ (with BSA)**                 0.0414          0.0552          0.038
  A2780                                               PDGF                                             **pAK^TS473^**                                 0.0588          0.0169          1.33
  CHO - Clone113                                      stable over-expression of TIE2                   **pTIE2^pY99^**                                0.166           \>10            0.327
  HEK293-Clone 25                                     stable over-expression of EphB4                  **pEphB4^Y590/Y596^**                          0.0091          3.013           0.337
  **Cell-Based Antiproliferation Assay IC50 (μM**)                                                                                                                                    
                                                                                                                                                      **LY2457546**   **Sunitinib**   **Sorafenib**
  MV4-11                                              constitutively active (FLT3 ITD Mutation D835)                                                  0.000339        0.0196          0.0117

**Notes:**

Percent inhibition at 20 μM;

Stable overexpression of pTIE2.

**Abbreviations:** HUVEC, human umbilical endothelial vascular cells; ND, not determined; BSA, bovine serum albumin.

###### 

Baseline patient and disease characteristics (n = 5)

  -------------------------------------- ------------------------------------------ -----------
  Gender                                 Male                                       3

                                         Female                                     2

  Age group (years)                      ≤60                                        1

                                         \>60                                       4

  ECOG performance status                0\                                         2\
                                         1                                          3

  Pathological diagnosis                 Primary AML\                               4\
                                         Secondary AML (myelodysplastic syndrome)   1

  Time since initial diagnosis (years)   ≤1.5\                                      4\
                                         \>1.5                                      1

  Prior antileukemia therapy             Induction only                             1

                                         Induction/consolidation                    4

                                         Number of regimen                          

                                         ≤1                                         1

                                         \>1                                        4

  Historical illness                     Prostate cancer                            3

                                         Cholelithiasis                             1

                                         Venous thrombosis                          2

                                         Diverticulosis                             1

                                         Duodenal ulcer                             1

                                         Facial paresis                             1

                                         Goiter                                     1

                                         Invertebral disc protrusion                1

                                         Myelodysplastic syndrome                   1

                                         Osteoarthritis                             1

                                         Pneunomia                                  1

                                         Polymyalgia rheumatica                     1

  Karyotype                              46,XX,t(9;11)                              Patient A

                                         46,XY,t(X;2)/47,XY,t(2;X) + 9/46,XY        Patient B

                                         47,XY,+8/46,XY                             Patient C

                                         46,XY,del(11)                              Patient D

                                         46,XX,del,(12),del(20)/46,XX               Patient E
  -------------------------------------- ------------------------------------------ -----------

**Abbreviations:** AML, acute myeloid leukemia; ECOG, Eastern Cooperative Oncology Group.

###### 

Overview of all adverse events[\*](#tfn7-cmr-3-157){ref-type="table-fn"} regardless of causality (n = 5 patients)

                                                         **Maximum CTC grade**           
  ------------------------------------------------------ ----------------------- --- --- ---
  System organ class                                                                     
    Preferred term                                       1                       2   3   4
  Blood and lymphatic system disorders                                                   
    Febrile neutropenia                                                              2   
    Splenomegaly                                         1                               
  Ear and labyrinthine disorders                                                         
    Vertigo                                              1                               
  Eye disorders                                                                          
    Keratoconjunctivitis sicca                                                   1       
  Gastrointestinal disorders                                                             
    Chapped lips                                         1                               
    Ulcerative colitis                                   1                               
    Constipation                                         1                       1       
    Diarrhea                                             2                               
    Gingival hyperplasia                                                         1       
    Hemorrhoids                                          1                       1       
    Inguinal hernia                                      1                               
    Nausea                                               1                               
    Stomatitis                                                                   1       
  General disorders and administration site conditions                                   
    Asthenia (muscle weakness)                                                       1   
    Fatigue                                              1                               
    Peripheral edema                                     1                               
  Hepatobiliary disorders                                                                
    Hepatomegaly                                         1                               
  Infections                                                                             
    Anal abscess                                                                     1   
    Breast cellulitis                                                                1   
    Catheter-related infection                                                       1   
    Fungal sepsis                                                                    1   
    Neutropenic sepsis                                                               1   
    Pneumonia                                                                            
  Metabolism and nutrition disorders                                                     
    Hypokalemia                                          3                               
    Hypophosphatemia                                                                     1
  Musculoskeletal and connective tissue disorders                                        
    Back pain                                                                    1       
    Musculoskeletal pain                                 1                               
    Osteoporosis                                         1                               
  Neoplasms (benign, malignant, and unspecified)                                         
    Hemangioma of liver                                  1                               
  Nervous system disorders                                                               
    Headache                                             3                               
  Psychiatric disorders                                                                  
    Anxiety                                                                      2       
    Insomnia                                                                     1       
  Renal and urinary disorders                                                            
    Bladder spasm                                                                1       
    Hematuria                                            1                               
    Nephrolithiasis                                      1                               
  Respiratory, thoracic and mediastinal disorders                                        
    Asthma                                                                       1       
    Cough                                                1                               
    Epistaxis                                            1                       2       
    Oropharyngeal pain                                   1                               
  Skin and subcutaneous tissue disorders                                                 
    Hyperhidrosis                                        1                               
    Petechiae                                            3                               
    Facial swelling                                      1                               
    Urticaria                                                                    1       
  Vascular disorders                                                                     
    Hematoma                                             1                               
    Hemorrhage                                                                           1
    Hypertension                                                                 2       
    Hypotension                                                                      1   

**Note:**

Adverse events are included in this table starting from first dose of LY2457546.

**Abbreviation:** CTC, Common Toxicity Criteria.

###### 

Pharmacokinetic parameters following single and multiple oral doses of LY2457546 50 mg

  **Subject**   **T~max~ (h)**   **C~max~ (ng/mL)**   **T~last~(h)**   **C~last~ (ng/mL)**   **AUC~last~ (h\*ng/mL)**   **AUC0_24 (h\*ng/mL)**
  ------------- ---------------- -------------------- ---------------- --------------------- -------------------------- ------------------------
  **Visit 0**                                                                                                           
  A             48               154.876              48               154.876               6030                       2520
  B             2                604.581              48               302.003               16100                      8930
  C             4                2406.55              48               1354.06               79200                      41500
  D             24               105.113              24               105.113               1850                       1850
  E             2                394.238              24               78.459                3420                       3420
  N             5                5                    5                5                     5                          5
  Min           2                105.113              24               78.459                1850                       1850
  Max           48               2406.55              48               1354.06               79200                      41500
  **Visit 1**                                                                                                           
  A             0                619.909              24               607.429               12800                      12800
  B             8                591.772              24               513.075               12700                      12700
  C             2                3812.913             24               2830.537              69200                      69100
  D             2                1792.419             8                1373.021              11300                      nc
  E             4                123.44               48               28.097                3610                       2320
  N             5                5                    5                5                     5                          3
  Min           0                123.44               8                28.097                3610                       2320
  Max           8                3812.913             48               2830.537              69200                      69100
  **Visit 2**                                                                                                           
  A             0                1087.972             48               708.777               38400                      18500
  D             48               2190.006             48               2190.006              93400                      41500
  N             2                2                    2                2                     2                          2
  Min           0                1087.972             48               708.777               38400                      18500
  Max           48               2190.006             48               2190.006              93400                      41500

**Abbreviations:** T~max~, time to maximum concentration; C~max~, maximum plasma concentration; T~last~, last time to maximum concentration; C~last~, last plasma concentration; AUC~last~, last area under the plasma concentration versus time curve; min, minimum; max, maximum.
